An Extension Study of TAK-664 for Japanese People With Primary Immunodeficiency Disease
A legfontosabb adatok
- Ki végzi
- Takeda
- Hol
- Japán8 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- NCT04842643
- JRCT2041210006
- U1111-1265-9447
- Állapot
- Befejeződött
- Fázis
- 3. fázis
- Résztvevők
- 12 fő vett részt
- Kezdés
- 2021. ápr. 27.
- Befejezés
- 2024. ápr. 25.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- IGSC 20% infusion
- A regiszteradat frissítve
- 2025. január 20.
Ki vehet részt
- Életkor
- 2 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 6 feltétel megnézéseKevesebb
Ki vehet részt
- Participant has completed or is about to complete Takeda Clinical Study TAK-664-3001; A participant is considered to have completed Study TAK-664-3001 successfully if they fulfill the following criterion: Completed Epoch 2, in which IGSC, 20% is administered weekly (completion of Epoch 3, in which IGSC, 20% is administered biweekly, is not mandatory for participation in TAK-664-3002 study)
- Written informed consent is obtained from either the Participant or the Participant's legally authorized representative prior to any study-related procedures and study product administration
- Participant is willing and able to comply with the requirements of the protocol
Ki nem vehet részt
- Participant is scheduled to participate in another non-Takeda clinical study involving an Investigational Product or device-used-in-clinical-trial in the course of this study
- Participant has developed a new serious medical condition during participation in Study TAK-664-3001 such that the Participant's safety or medical care would be impacted by participation in the extension study TAK-664-3002
- If a female of childbearing potential, Participant is pregnant or has a negative pregnancy test but does not agree to employ adequate birth control measures for the duration of the study
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
This study is an extension study for participants with primary immunodeficiency disorders who were previously treated with IGSC, 20% in the TAK-664-3001 study. They must have completed that study or be about to complete it before joining this study. Participants will continue treatment with IGCS, 20% in this study.
A teljes eredeti leírásKevesebb
The main aim of this study is to check for side effects from long-term treatment with IGSC, 20% . This medicine is not yet licensed in Japan, so participants will be treated with IGSC, 20% until it becomes commercially available.
A vizsgálat csoportja
- IGSC, 20%A vizsgált kezelés
Participants who completed Epoch 2 of core study TAK-664-3001 (NCT04346108), received between 50 to 200 mg/kg of Immune globulin subcutaneous (IGSC) infusion, 20% infusion once a week (Epoch 2 regimen) and 100 to 400 mg/kg of IGSC infusion, 20% biweekly (Epoch 3 regimen) until the study drug becomes commercially available.
Kezelés: IGSC 20% infusion
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Phase 3, Open-label, Non-controlled, Multi-dose, Extension Study to Evaluate the Long-term Safety and Tolerability of IGSC, 20% in Japanese Subjects With Primary Immunodeficiency Disease (PID)
- A regiszteradat frissítve
- 2025. január 20.